Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

735 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2).
Vera P, Mezzani-Saillard S, Edet-Sanson A, Ménard JF, Modzelewski R, Thureau S, Meyer ME, Jalali K, Bardet S, Lerouge D, Houzard C, Mornex F, Olivier P, Faure G, Rousseau C, Mahé MA, Gomez P, Brenot-Rossi I, Salem N, Dubray B. Vera P, et al. Among authors: salem n. Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1057-65. doi: 10.1007/s00259-014-2687-9. Epub 2014 Feb 22. Eur J Nucl Med Mol Imaging. 2014. PMID: 24562641 Clinical Trial.
Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by 18F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study).
Vera P, Thureau S, Chaumet-Riffaud P, Modzelewski R, Bohn P, Vermandel M, Hapdey S, Pallardy A, Mahé MA, Lacombe M, Boisselier P, Guillemard S, Olivier P, Beckendorf V, Salem N, Charrier N, Chajon E, Devillers A, Aide N, Danhier S, Denis F, Muratet JP, Martin E, Riedinger AB, Kolesnikov-Gauthier H, Dansin E, Massabeau C, Courbon F, Farcy Jacquet MP, Kotzki PO, Houzard C, Mornex F, Vervueren L, Paumier A, Fernandez P, Salaun M, Dubray B. Vera P, et al. Among authors: salem n. J Nucl Med. 2017 Jul;58(7):1045-1053. doi: 10.2967/jnumed.116.188367. Epub 2017 Mar 2. J Nucl Med. 2017. PMID: 28254869 Free article. Clinical Trial.
Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET.
Gravis G, Autret A, Guibert-Broudic M, Dubergé T, Zemmour C, Carrier P, Salem N, Badinand D, Cartier L, Gross E, Walz J, Pignot G, Brenot-Rossi I. Gravis G, et al. Among authors: salem n. Clin Genitourin Cancer. 2021 Aug;19(4):346-353. doi: 10.1016/j.clgc.2021.03.004. Epub 2021 Mar 16. Clin Genitourin Cancer. 2021. PMID: 33849812
Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer.
Masson I, Larriviere L, Mahé MA, Azria D, Pommier P, Mesgouez-Nebout N, Giraud P, Peiffert D, Chauvet B, Dudouet P, Salem N, Noël G, Khalifa J, Latorzeff I, Guérin-Charbonnel C, Supiot S. Masson I, et al. Among authors: salem n. Clin Transl Radiat Oncol. 2023 Nov 17;44:100702. doi: 10.1016/j.ctro.2023.100702. eCollection 2024 Jan. Clin Transl Radiat Oncol. 2023. PMID: 38111609 Free PMC article.
70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial.
Beckendorf V, Guerif S, Le Prisé E, Cosset JM, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud JM, Maingon P, Hannoun-Levi JM, Malissard L, Simon JM, Pommier P, Hay M, Dubray B, Lagrange JL, Luporsi E, Bey P. Beckendorf V, et al. Among authors: salem n. Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1056-63. doi: 10.1016/j.ijrobp.2010.03.049. Epub 2010 Dec 14. Int J Radiat Oncol Biol Phys. 2011. PMID: 21147514 Clinical Trial.
Brachytherapy for oligometastatic prostate cancer to the penis.
Martz N, Benziane-Ouaritini N, Gautier M, Brenot-Rossi I, Montagne L, Salem N, Bodokh Y, Hannoun-Levi JM. Martz N, et al. Among authors: salem n. J Contemp Brachytherapy. 2021 Oct;13(5):593-597. doi: 10.5114/jcb.2021.109754. Epub 2021 Oct 6. J Contemp Brachytherapy. 2021. PMID: 34759985 Free PMC article.
The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity.
Beckendorf V, Guérif S, Le Prisé E, Cosset JM, Lefloch O, Chauvet B, Salem N, Chapet O, Bourdin S, Bachaud JM, Maingon P, Lagrange JL, Malissard L, Simon JM, Pommier P, Hay MH, Dubray B, Luporsi E, Bey P. Beckendorf V, et al. Among authors: salem n. Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1056-65. doi: 10.1016/j.ijrobp.2004.05.033. Int J Radiat Oncol Biol Phys. 2004. PMID: 15519775 Clinical Trial.
High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study).
Hannoun-Levi JM, Ortholan C, Resbeut M, Teissier E, Ronchin P, Cowen D, Zaccariotto A, Bénézery K, François E, Salem N, Ellis S, Azria D, Gerard JP. Hannoun-Levi JM, et al. Among authors: salem n. Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):712-20. doi: 10.1016/j.ijrobp.2010.02.055. Epub 2010 Jul 7. Int J Radiat Oncol Biol Phys. 2011. PMID: 20619552
Cost and Toxicity Comparisons of Two IMRT Techniques for Prostate Cancer: A Micro-Costing Study and Weighted Propensity Score Analysis Based on a Prospective Study.
Masson I, Bellanger M, Perrocheau G, Mahé MA, Azria D, Pommier P, Mesgouez-Nebout N, Giraud P, Peiffert D, Chauvet B, Dudouet P, Salem N, Noël G, Khalifa J, Latorzeff I, Guérin-Charbonnel C, Supiot S. Masson I, et al. Among authors: salem n. Front Oncol. 2022 Jan 11;11:781121. doi: 10.3389/fonc.2021.781121. eCollection 2021. Front Oncol. 2022. PMID: 35087753 Free PMC article.
735 results